| Day | Date | AM/PM | Session | Agenda | Chair | Scribe | Co-Chair
Availability | Room |
|---|
| Sunday | February 2, 2020 | AM | Q1 | Not Meeting |
|
|
|
|
| AM | Q2 | Not Meeting |
|
|
|
|
| AM | Q3 | Not Meeting |
|
|
|
|
| AM | Q4 | Not Meeting |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Monday | February 3, 2020 | AM | Q1 | Not Meeting |
|
|
|
|
| AM | Q2 | Not Meeting |
|
|
|
|
| PM | Q3 | Not Meeting |
|
|
|
|
| PM | Q4 | Not Meeting |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tuesday | February 4, 2020 | AM | Q1 | Meeting - Review Agenda
- Reps to other WGs
- Wed Q2 - O&O - HealthcareProduct: Substance, Substance Definition, BiologicallyDerivedProduct, Supply, Medication, MedicinalProduct, MedicationKnowledge - Scott
- Wed Q4 - Public Health - confirmed with Public Health that there are no agenda topics
- Thurs Q3 - CDS - will cancel and all go to CDS
- Fri Q1 - Patient Care - Care Plan report out - Scott
- Assign Roles for Quarters
- Approval of September 2019 WGM Minutes
- If we have new attendees, review
- Overview of Pharmacy material - V2, V3, FHIR
- Overview of Template work
- Hot Topics
- Prep for Joint FHIR meeting
| Jean | Melva | Melva Jean Scott | E3.3 |
| AM | Q2 | Meeting | Melva | Scott | Melva Scott | E3.3 |
| AM | Q3 | Meeting | Scott | Melva | Melva Jean Scott | E3.3 |
| PM | Q4 | Meeting - Discuss Medication List with Michelle Miller
| Melva | Jean | Melva Scott Jean | E3.3 |
|
|
|
|
|
|
|
|
|
| Wednesday | February 5, 2020 | AM | Q1 | Not Meeting |
|
|
|
|
| AM | Q2 | Not Meeting - Rep to O&O |
|
|
|
|
| PM | Q3 | Not Meeting |
|
|
|
|
| PM | Q4 | Not Meeting |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Thursday | February 6, 2020 | AM | Q1 | Meeting | Melva | Jean | Jean Melva ? Scott | E3C3.5 |
| AM | Q2 | Meeting | Scott | Melva | Jean Melva Scott | E3C3.5 |
| PM | Q3 | Not Meeting - CANCELLED
|
|
|
|
|
| PM | Q4 | Meeting - VA Pharmacy Project - Jay Lyle (material to be provided)
- Questions:
- Do these maps make sense? Are there assumptions I’m missing? Are there better approaches?
- Are there changes coming that might affect our approach?
- What other stakeholders would be interested in comparing extensions? What’s the best channel for that discussion?
- Attachments:
- VAPharmaMaps.xlsx
- Notes:
Columns A-J are VistA metadata. K-R are the proposed design description. There’s a legend for the column headers. The areas of most interest will be the orders in the area (B) column: Inpatient Orders - pending/non-verified Inpatient Orders IV/Clinic Infusions Inpatient Orders Unit Dose/Clinic Medications Outpatient Orders Outpatient Orders - pending Non-VA Medications
- DD19_20191122_1155_JayLyle_BalancingActExposingLegacyDataInFHIR.pptx
I also attach a slide deck for a high-level overview of what’s going on in there, for what it’s worth, which you can read or I can present, or both.
| Melva | Scott | Melva Scott | E3C3.5 |
|
|
|
|
|
|
|
|
|
| Friday | February 7, 2020 | AM | Q1 | Meeting - Rep to Patient Care Project Management - Schedule for Conference calls
- DMP - 2018
- M&C - 2018
- SWOT - 2018
- Reaffirmation/Withdrawal of 5 year items
- Forward Planning
- Project Review
- Action Item list review
- Addition of another chair
- WGM Meeting planning
- CDS - Wednesday Q3 - do we want to do full joint or just send reps
- BR&R - Monday Q3 - will join BR&R
- FHIR-1
| Melva | Melva | Jean Melva
| E3.5 |
| AM | Q2 | Joint Meeting with FHIR-I - Pharmacy Hosting | Jean | Melva | Jean Melva Scott | E3.5 |
| PM | Q3 | Not Meeting |
|
|
|
|
| PM | Q4 | Not Meeting |
|
|
|
|
